Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07422675 · ClinicalTrials.gov registry record · Phase 1
SAD Study in Patients With Parkinson's Disease and Motor Fluctuations
A Phase 1 study of PARKINSON DISEASE (Disorder) and Advanced Parkinson's Disease, sponsored by Serina Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
- 4
- Study locations
NCT07422675: Recruiting Phase 1 study of PARKINSON DISEASE (Disorder) and Advanced Parkinson's Disease, sponsored by Serina Therapeutics.
NCT07422675 is a Phase 1 study of PARKINSON DISEASE (Disorder) and Advanced Parkinson's Disease that is actively recruiting participants, run by Serina Therapeutics. The registered enrollment target is 40 participants, roughly in line with the 37-participant average among 5 other PARKINSON DISEASE (Disorder) trials with a reported enrollment target. The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07422675, a Phase 1 study of PARKINSON DISEASE (Disorder) and Advanced Parkinson's Disease, is actively recruiting participants, sponsored by Serina Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
- 4
- Study locations
Study Summary
This is a randomized, placebo-controlled, single ascending dose (SAD) study of SER-252 in participants with Parkinson's Disease (PD) and motor fluctuations.
Primary Outcome
Proportion of participants with TEAEs (new onset or worsening) and temporal profile post-dose; TEAEs summarized by type/nature, severity/intensity, seriousness, and relationship to study treatment per protocol.
Conditions Studied
Interventions
- DRUG SER-252 (PEOZ-apomorphine)
- DEVICE enFuse
Study Locations (4)
Florida
- Quest Research Institute - Lake Mary
North Carolina
- Velocity Clinical Research - Durham
South Australia
- CMAX - Adelaide
Victoria
- Monash - Melbourne
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2026-02-01 |
| Est. Completion | 2027-01-31 |
| Phase | Phase 1 |
What NCT07422675 shows while recruiting
NCT07422675 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, roughly in line with the 37-participant average among 5 other PARKINSON DISEASE (Disorder) trials with a reported enrollment target.
The record links to 2 conditions, with PARKINSON DISEASE (Disorder) appearing as the primary indexed condition, and to 2 interventions - of which SER-252 (PEOZ-apomorphine) is the first listed.
NCT07422675 reports a single indexed study location in Florida, North Carolina, South Australia.
Frequently Asked Questions
What is clinical trial NCT07422675 about?
NCT07422675 is a clinical study titled "SAD Study in Patients With Parkinson's Disease and Motor Fluctuations". This is a randomized, placebo-controlled, single ascending dose (SAD) study of SER-252 in participants with Parkinson's Disease (PD) and motor fluctuations.
What is the current status of trial NCT07422675?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2026-02-01. Estimated completion is 2027-01-31.
What conditions does trial NCT07422675 study?
This clinical trial studies the following conditions: PARKINSON DISEASE (Disorder), Advanced Parkinson's Disease.
What interventions are being tested in trial NCT07422675?
The interventions under investigation include: SER-252 (PEOZ-apomorphine) (DRUG), enFuse (DEVICE).
Who is sponsoring clinical trial NCT07422675?
This trial is sponsored by Serina Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07422675 being conducted?
This trial has 4 study locations across Florida, North Carolina, South Australia, Victoria. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for PARKINSON DISEASE (Disorder)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Virtual tES Device Treatment for Parkinson's Disease Motor Symptoms
RECRUITING · Phase 1
-
Colonoscopic Detection of Phosphorylated Alpha-synuclein for Parkinson's Diagnosis
RECRUITING
-
Colonic Tissue Biopsy Detection of Phosphorylated Alpha-synuclein for Parkinson's Diagnosis or REM Sleep Behavior Disorder
RECRUITING
-
Effects of Vagal Nerve Stimulation on Leg Muscle Activity and Posture in Parkinson's Disease
RECRUITING · NA
-
Open Label Single Arm Prebiotic Pilot Trial SR001
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI